| 将分子遗传学通路作为急性髓性白血病治疗的靶点 |
| |
| 引用本文： | 王耀平.将分子遗传学通路作为急性髓性白血病治疗的靶点[J].实用医院临床杂志,2010,7(2):41-45. |
| |
| 作者姓名： | 王耀平 |
| |
| 作者单位： | 上海交通大学医学院上海儿童医学中心血液肿瘤科,上海,200127 |
| |
| 摘 要： | 急性髓性白血病(AML)的异质性是由一系列细胞遗传学异常和分子突变引起的。遗传学标记是对AML不同亚型进行分类的基础,可预测预后,并影响治疗的策略。随着分子的反复变异对治疗方案的影响日益深入,我们在遗传学确定不同的相同亚型上依然能找到临床变异,这部分关系到不同变异和正常核型AML不同分型的交互作用。与这些重要发现相吻合,多种不同类型的新化合物已进入临床前和临床试验,其目的在于通过干预分子遗传学或表观遗传学机制形成靶向治疗的概念。本文简述近年来最常见的相关遗传学标记,作为现代和将来靶向治疗的基础以及最近靶向治疗研究的结果。
|
| 关 键 词： | 分子遗传学通路 急性髓性白血病 靶向治疗 |
Molecular genetic pathway:A target used for treatment of acute myeloid leukemia |
| |
| WANG Yao-ping.Molecular genetic pathway:A target used for treatment of acute myeloid leukemia[J].Practical Journal of Clinical Medicine,2010,7(2):41-45. |
| |
| Authors: | WANG Yao-ping |
| |
| Institution: | WANG Yao-ping (Department of Hematology , Oncology,Shanghai Children\'s Medical Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China) |
| |
| Abstract: | The heterogeneity of acute myeloid leukemia (AML) results from a complex network of cytogenetic aberration and molecular mutation.Genetic markers are the basis for stratifying different subgroups of AML patients.They can possibly predict the prognosis and affect treatment strategies.Clinical variances still could be found even in the same distinct genetic defined subgroups,partly being linked to the interaction of diverse mutations and the subdivision of Normal karyotype AML on the basis of recurrent mutati... |
| |
| Keywords: | Molecular genetic pathway AML Targeted therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
